Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
3.16
P/B Ratio
0.31
Industry P/E
--
Debt to Equity
0.13
ROE
-0.03 %
ROCE
-11.14 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-82.64 Mln
EBITDA
$-95.29 Mln
Net Profit
$-66.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -65.72 | 8.46 | -12.74 | -81.82 | -54.66 | -51.01 | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -55.48 | -63.33 | -39.27 | -84.42 | 4.41 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.07 | 0.99 | 0.38 | 1 | |
| 9.50 | 487.51 | -- | -29.04 | |
| 4.38 | 2.26 | -- | -14.34 |
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases.... The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Address: 17 Hanover Square, London, United Kingdom, W1S 1BN Read more
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aptorum Group Limited Class A - ADR stood at $ 21 Mln as on 31-Dec-23
The share price of Aptorum Group Limited Class A - ADR is $0.96 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Aptorum Group Limited Class A - ADR has given a return of -54.66% in the last 3 years.
Aptorum Group Limited Class A - ADR has a market capitalisation of $ 7 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Aptorum Group Limited Class A - ADR is 3.16 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aptorum Group Limited Class A - ADR and enter the required number of quantities and click on buy to purchase the shares of Aptorum Group Limited Class A - ADR.
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Address: 17 Hanover Square, London, United Kingdom, W1S 1BN
The CEO & director of Mr. Chung Yuen Huen. is Aptorum Group Limited Class A - ADR, and CFO & Sr. VP is Mr. Chung Yuen Huen.
There is no promoter pledging in Aptorum Group Limited Class A - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
49
|
|
|
1
|
|
|
0
|
|
|
49
|
| Aptorum Group Limited Class A - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-13.93
|
|
Operating margin(%)
|
-2486.04
|
|
Net Margin(%)
|
-654.8
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aptorum Group Limited Class A - ADR was No Profit.
$-0.02
(
